Type I interferons in anticancer immunity
Abstract
Type I interferons (IFNs) are known for their key role in antiviral immune responses. In this Review, we discuss accumulating evidence indicating that type I IFNs produced by malignant cells or tumour-infiltrating dendritic cells also control the autocrine or paracrine circuits that underlie cancer immunosurveillance. Many conventional chemotherapeutics, targeted anticancer agents, immunological adjuvants and oncolytic viruses are only fully efficient in the presence of intact type I IFN signalling. Moreover, the intratumoural expression levels of type I IFNs or of IFN-stimulated genes correlate with favourable disease outcome in several cohorts of patients with cancer. Finally, new anticancer immunotherapies are being developed that are based on recombinant type I IFNs, type I IFN-encoding vectors and type I IFN-expressing cells.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
IFNAR1 and IFNGR1 appear to have pro-necroptotic functions.
“In this context, IFN alpha and beta receptor subunit 1 (IFNAR1) and IFN gamma receptor 1 (IFNGR1) also appear to have pro-necroptotic functions [520–523].”
From Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018. (2018) · cites this paper as [520]
Intact autophagy responses regulate the adjuvanticity and antigenicity of tumor cells, thereby promoting the establishment of the cancer-immunity cycle leading to CTL-dependent elimination of malignant cells.
“In contrast to these findings, intact autophagy responses regulate (i) the adjuvanticity (e.g., the capacity to emit danger signals that are preliminary to the recruitment of immune cells to the tumor bed) (Michaud et al, 2011; Zitvogel et al, 2015; Garg et al, 2016) and (ii) antigenicity of tumor cells (Caron et al, 2011; Ma et al, 2013c; Pietrocola et al, 2017), thereby promoting the establis”
From Autophagy in major human diseases (2021) · cites this paper as Zitvogel et al, 2015
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · see citing works
The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors
Kawai, T., & Akira, S. (2010) · Nature Immunology · doi:10.1038/ni.1863 · Cited by 9,304 · see citing works
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474 · see citing works
Self-citationInnate and adaptive immune cells in the tumor microenvironment
Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148 · see citing works
Virus interference. I. the interferon
Isaacs, A., & Lindenmann, J. (1957) · Proceedings of the Royal Society of London. Series B - Biological Sciences · doi:10.1098/rspb.1957.0048 · Cited by 3,451 · see citing works
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,087 · see citing works
Type I interferons in infectious disease
McNab, F., Mayer-Barber, K., Sher, A., Wack, A., & O'Garra, A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3787 · Cited by 2,780 · see citing works
Deng, L., Liang, H., Xu, M., Yang, X., Burnette, B., Arina, A., Li, X.-D., Mauceri, H., Beckett, M., Darga, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.019 · Cited by 2,182 · see citing works
STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors
Woo, S.-R., Fuertes, M. B., Corrales, L., Spranger, S., Furdyna, M. J., Leung, M. Y. K., Duggan, R., Wang, Y., Barber, G. N., Fitzgerald, K. A., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.017 · Cited by 1,917 · see citing works
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Lu, G., Middleton, R. E., Sun, H., Naniong, M., Ott, C. J., Mitsiades, C. S., Wong, K.-K., Bradner, J. E., & Kaelin, W. G. (2014) · Science · doi:10.1126/science.1244917 · Cited by 1,583 · see citing works
STING is a direct innate immune sensor of cyclic di-GMP
Burdette, D. L., Monroe, K. M., Sotelo-Troha, K., Iwig, J. S., Eckert, B., Hyodo, M., Hayakawa, Y., & Vance, R. E. (2011) · Nature · doi:10.1038/nature10429 · Cited by 1,570 · see citing works
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death
Casares, N., Pequignot, M. O., Tesniere, A., Ghiringhelli, F., Roux, S., Chaput, N., Schmitt, E., Hamai, A., Hervas-Stubbs, S., Obeid, M., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050915 · Cited by 1,512 · see citing works
Self-citationAdaptive immunity maintains occult cancer in an equilibrium state
Koebel, C. M., Vermi, W., Swann, J. B., Zerafa, N., Rodig, S. J., Old, L. J., Smyth, M. J., & Schreiber, R. D. (2007) · Nature · doi:10.1038/nature06309 · Cited by 1,438 · see citing works
Self-citationViruses and interferon: a fight for supremacy
Katze, M. G., He, Y., & Gale, M. (2002) · Nature Reviews Immunology · doi:10.1038/nri888 · Cited by 1,419 · see citing works
Broz, M. L., Binnewies, M., Boldajipour, B., Nelson, A. E., Pollack, J. L., Erle, D. J., Barczak, A., Rosenblum, M. D., Daud, A., Barber, D. L., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.007 · Cited by 1,207 · see citing works
Type I interferon is selectively required by dendritic cells for immune rejection of tumors
Diamond, M. S., Kinder, M., Matsushita, H., Mashayekhi, M., Dunn, G. P., Archambault, J. M., Lee, H., Arthur, C. D., White, J. M., Kalinke, U., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101158 · Cited by 1,081 · see citing works
Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
Sistigu, A., Yamazaki, T., Vacchelli, E., Chaba, K., Enot, D. P., Adam, J., Vitale, I., Goubar, A., Baracco, E. E., Remédios, C., et al. (2014) · Nature Medicine · doi:10.1038/nm.3708 · Cited by 1,042 · see citing works
Self-citationApoptotic Caspases Suppress mtDNA-Induced STING-Mediated Type I IFN Production
White, M. J., McArthur, K., Metcalf, D., Lane, R. M., Cambier, J. C., Herold, M. J., van Delft, M. F., Bedoui, S., Lessene, G., Ritchie, M. E., et al. (2014) · Cell · doi:10.1016/j.cell.2014.11.036 · Cited by 983 · see citing works
Burnette, B., Liang, H. L., Lee, Y., Chlewicki, L. K., Khodarev, N. N., Weichselbaum, R. R., Fu, Y., & Auh, S. L. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2820 · Cited by 883 · see citing works
Zitvogel, L., Galluzzi, L., Smyth, M. J., & Kroemer, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.06.014 · Cited by 879 · see citing works
Self-citationApoptotic Caspases Prevent the Induction of Type I Interferons by Mitochondrial DNA
Rongvaux, A., Jackson, R., Harman, C. C. D., Li, T., West, A. P., de Zoete, M. R., Wu, Y., Yordy, B., Lakhani, S. A., Kuan, C.-Y., et al. (2014) · Cell · doi:10.1016/j.cell.2014.11.037 · Cited by 847 · see citing works
Type I interferon: friend or foe?
Trinchieri, G. (2010) · The Journal of Experimental Medicine · doi:10.1084/jem.20101664 · Cited by 844 · see citing works
Alpha Interferon for Induction of Remission in Hairy-Cell Leukemia
Quesada, J. R., Reuben, J. M., Manning, J. T., Hersh, E. M., & Gutterman, J. U. (1984) · New England Journal of Medicine · doi:10.1056/nejm198401053100104 · Cited by 817 · see citing works
Identification of a dendritic cell receptor that couples sensing of necrosis to immunity
Sancho, D., Joffre, O. P., Keller, A. M., Rogers, N. C., Martínez, D., Hernanz-Falcón, P., Rosewell, I., & Sousa, C. R. E. (2009) · Nature · doi:10.1038/nature07750 · Cited by 750 · see citing works
Mitochondria: master regulators of danger signalling
Galluzzi, L., Kepp, O., & Kroemer, G. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3479 · Cited by 733 · see citing works
Self-citationZamarin, D., Holmgaard, R. B., Subudhi, S. K., Park, J. S., Mansour, M., Palese, P., Merghoub, T., Wolchok, J. D., & Allison, J. P. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008095 · Cited by 711 · see citing works
Talpaz, M., Kantarjian, H. M., McCredie, K. B., Trujillo, J. M., Keating, M. J., & Gutterman, J. U. (1986) · New England Journal of Medicine · doi:10.1056/nejm198604243141701 · Cited by 644 · see citing works
Eggermont, A. M. M., Suciu, S., Santinami, M., Testori, A., Kruit, W. H. J., Marsden, J. R., Punt, C. J. A., Salès, F., Gore, M. E., MacKie, R. M., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61033-8 · Cited by 639 · see citing works
Plasmacytoid Dendritic Cells: Recent Progress and Open Questions
Reizis, B., Bunin, A., Ghosh, H. S., Lewis, K. L. T., & Sisirak, V. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101345 · Cited by 624 · see citing works
A critical function for type I interferons in cancer immunoediting
Dunn, G. P., Bruce, A. T., Sheehan, K. C. F., Shankaran, V., Uppaluri, R., Bui, J. D., Diamond, M. S., Koebel, C. M., Arthur, C. D., White, J. M., et al. (2005) · Nature Immunology · doi:10.1038/ni1213 · Cited by 611 · see citing works
IFN-α and IL-10 Induce the Differentiation of Human Type 1 T Regulatory Cells
Levings, M. K., Sangregorio, R., Galbiati, F., Squadrone, S., Malefyt, R. D. W., & Roncarolo, M. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.9.5530 · Cited by 595 · see citing works
RNA recognition and signal transduction by RIG‐I‐like receptors
Yoneyama, M., & Fujita, T. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00727.x · Cited by 594 · see citing works
Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma
Yang, Y., Shaffer, A. L., Emre, N. C. T., Ceribelli, M., Zhang, M., Wright, G. W., Xiao, W., Powell, J. I., Platig, J., Kohlhammer, H., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.05.024 · Cited by 524 · see citing works
Jonasch, E., & Haluska, F. G. (2001) · The Oncologist · doi:10.1634/theoncologist.6-1-34 · Cited by 520 · see citing works
Direct Effects of Type I Interferons on Cells of the Immune System
Hervás‐Stubbs, S., Perez‐Gracia, J. L., Rouzaut, A., Sanmamed, M. F., Bon, A. L., & Melero, I. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1114 · Cited by 504 · see citing works
Stagg, J., Loi, S., Divisekera, U., Ngiow, S. F., Duret, H., Yagita, H., Teng, M. W., & Smyth, M. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016569108 · Cited by 496 · see citing works
Self-citationSilencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape
Bidwell, B. N., Slaney, C. Y., Withana, N. P., Forster, S., Cao, Y., Loi, S., Andrews, D., Mikeska, T., Mangan, N. E., Samarajiwa, S. A., et al. (2012) · Nature Medicine · doi:10.1038/nm.2830 · Cited by 487 · see citing works
Self-citationClassification of current anticancer immunotherapies
Galluzzi, L., Vacchelli, E., Pedro, J. M. B., Buqué, A., Senovilla, L., Baracco, E. E., Bloy, N., Castoldi, F., Abastado, J., Agostinis, P., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2998 · Cited by 471 · see citing works
Self-citationAutophagy and cellular immune responses
Ma, Y., Galluzzi, L., Zitvogel, L., & Kroemer, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.017 · Cited by 447 · see citing works
Self-citationAhrens, S., Zelenay, S., Sancho, D., Hanč, P., Kjær, S., Feest, C., Fletcher, G., Durkin, C. H., Postigo, A. A., Skehel, M. J., et al. (2012) · Immunity · doi:10.1016/j.immuni.2012.03.008 · Cited by 393 · see citing works
Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia
Preudhomme, C., Guilhot, J., Nicolini, F. E., Guerci‐Bresler, A., Huguet, F., Maloisel, F., Coiteux, V., Gardembas, M., Berthou, C., Vekhoff, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1004095 · Cited by 389 · see citing works
5′-triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma
Poeck, H., Besch, R., Maihoefer, C., Renn, M., Tormo, D., Morskaya, S. S., Kirschnek, S., Gaffal, E., Landsberg, J., Hellmuth, J., et al. (2008) · Nature Medicine · doi:10.1038/nm.1887 · Cited by 387 · see citing works
Plasmacytoid dendritic cells sense skin injury and promote wound healing through type I interferons
Gregorio, J., Meller, S., Conrad, C., Di Nardo, A., Homey, B., Lauerma, A., Arai, N., Gallo, R. L., DiGiovanni, J., & Gilliet, M. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20101102 · Cited by 367 · see citing works
PRIMARY SEX-RATIO AND SIZE OF FAMILY
Shokeir, M. H. K. (1970) · The Lancet · doi:10.1016/s0140-6736(70)90607-0 · Cited by 366 · see citing works
Schiavoni, G., Sistigu, A., Valentini, M., Mattei, F., Sestili, P., Spadaro, F., Sanchez, M., Lorenzi, S., D'Urso, M. T., Belardelli, F., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2788 · Cited by 362 · see citing works
Sisirak, V., Faget, J., Gobert, M., Goutagny, N., Vey, N., Treilleux, I., Renaudineau, S., Poyet, G., Labidi‐Galy, S. I., Goddard‐Léon, S., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3468 · Cited by 346 · see citing works
Type I IFN Contributes to NK Cell Homeostasis, Activation, and Antitumor Function
Swann, J. B., Hayakawa, Y., Zerafa, N., Sheehan, K. C. F., Scott, B., Schreiber, R. D., Hertzog, P. J., & Smyth, M. J. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.12.7540 · Cited by 340 · see citing works
Self-citationProduction of type I interferons
Asselin‐Paturel, C., & Trinchieri, G. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051395 · Cited by 304 · see citing works
Drobits, B., Holcmann, M., Amberg, N., Swiecki, M. K., Grundtner, R., Hammer, M., Colonna, M., & Sibilia, M. C. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61034 · Cited by 295 · see citing works
Eggermont, A. M. M., Suciu, S., Testori, A., Santinami, M., Kruit, W. H. J., Marsden, J. R., Punt, C. J. A., Salès, F., Dummer, R., Robert, C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.3799 · Cited by 278 · see citing works
INTERFERON THERAPY IN MYELOMATOSIS
Mellstedt, H., Björkholm, M., Johansson, B., Åhre, A., Holm, G., & Strander, H. A. (1979) · The Lancet · doi:10.1016/s0140-6736(79)90770-0 · Cited by 275 · see citing works
Treatment of Advanced Non-Hodgkin's Lymphoma with Recombinant Leukocyte a Interferon
Foon, K. A., Sherwin, S. A., Abrams, P. G., Longo, D. L., Fer, M. F., Stevenson, H. C., Ochs, J. J., Bottino, G. C., SCHOENBERGER, C., Zeffren, J., et al. (1984) · New England Journal of Medicine · doi:10.1056/nejm198411013111803 · Cited by 274 · see citing works
Zelenay, S., Keller, A. M., Whitney, P. G., Schraml, B. U., Deddouche, S., Rogers, N. C., Schulz, O., Sancho, D., & Sousa, C. R. E. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60644 · Cited by 272 · see citing works
Targeting the Tumor Microenvironment with Interferon-β Bridges Innate and Adaptive Immune Responses
Yang, X., Zhang, X., Fu, M. L., Weichselbaum, R. R., Gajewski, T. F., Guo, Y., & Fu, Y. (2014) · Cancer Cell · doi:10.1016/j.ccr.2013.12.004 · Cited by 269 · see citing works
Structural basis of a unique interferon-β signaling axis mediated via the receptor IFNAR1
de Weerd, N. A., Vivian, J. P., Nguyen, T. K., Mangan, N. E., Gould, J. A., Braniff, S.-J., Zaker-Tabrizi, L., Fung, K. Y., Forster, S. C., Beddoe, T., et al. (2013) · Nature Immunology · doi:10.1038/ni.2667 · Cited by 260 · see citing works
Immune Cell–Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation
Bald, T., Landsberg, J., Lopez-Ramos, D., Renn, M., Glodde, N., Jansen, P., Gaffal, E., Steitz, J., Tolba, R. H., Kalinke, U., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0458 · Cited by 256 · see citing works
Gajewski, T. F., Louahed, J., & Brichard, V. G. (2010) · The Cancer Journal · doi:10.1097/ppo.0b013e3181eacbd8 · Cited by 250 · see citing works
Interferons and Their Stimulated Genes in the Tumor Microenvironment
Cheon, H., Borden, E. C., & Stark, G. R. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.02.002 · Cited by 250 · see citing works
Novikov, A., Cardone, M., Thompson, R. W., Shenderov, K., Kirschman, K. D., Mayer-Barber, K. D., Myers, T. G., Rabin, R. L., Trinchieri, G., Sher, A., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100926 · Cited by 243 · see citing works
Moschos, S. J., Edington, H. D. J., Land, S. R., Rao, U. N. M., Jukic, D. M., Shipe-Spotloe, J. M., & Kirkwood, J. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.2498 · Cited by 242 · see citing works
Type I Interferons Protect T Cells against NK Cell Attack Mediated by the Activating Receptor NCR1
Crouse, J., Bedenikovic, G., Wiesel, M., Ibberson, M. R., Xénarios, I., von Laer, D., Kalinke, U., Vivier, É., Jonjić, S., & Oxenius, A. (2014) · Immunity · doi:10.1016/j.immuni.2014.05.003 · Cited by 229 · see citing works
Type I Interferon Protects Antiviral CD8+ T Cells from NK Cell Cytotoxicity
Xu, H. C., Grusdat, M., Pandyra, A. A., Polz, R., Huang, J., Sharma, P., Deenen, R., Köhrer, K., Rahbar, R., Diefenbach, A., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.05.004 · Cited by 227 · see citing works
Hepatic RIG-I Predicts Survival and Interferon-α Therapeutic Response in Hepatocellular Carcinoma
Hou, J., Zhou, Y., Zheng, Y., Fan, J., Zhou, W., Ng, I. O., Sun, H., Qin, L., Qiu, S., Lee, J. M. F., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.11.011 · Cited by 221 · see citing works
Recognition of tumor cells by Dectin-1 orchestrates innate immune cells for anti-tumor responses
Chiba, S., Ikushima, H., Ueki, H., Yanai, H., Kimura, Y., Hangai, S., Nishio, J., Negishi, H., Tamura, T., Saijo, S., et al. (2014) · eLife · doi:10.7554/elife.04177 · Cited by 217 · see citing works
Linsley, P. S., Speake, C., Whalen, E., & Chaussabel, D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109760 · Cited by 210 · see citing works
Simonsson, B., Gedde‐Dahl, T., Markevärn, B., Remes, K., Stentoft, J., Almqvist, A., Björeman, M., Flogegård, M., Koskenvesa, P., Lindblom, A., et al. (2011) · Blood · doi:10.1182/blood-2011-02-336685 · Cited by 194 · see citing works
Mullally, A., Bruedigam, C., Poveromo, L., Heidel, F. H., Purdon, A. S., Vu, T., Austin, R. J., Heckl, D., Breyfogle, L. J., Kuhn, C. P., et al. (2013) · Blood · doi:10.1182/blood-2012-05-432989 · Cited by 189 · see citing works
Burchert, A., Müller, M. C., Kostrewa, P., Erben, P., Bostel, T., Liebler, S., Hehlmann, R., Neubauer, A., & Hochhaus, A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.5075 · Cited by 174 · see citing works
Interferon-dependent IL-10 production by Tregs limits tumor Th17 inflammation
Stewart, C. A., Metheny, H., Iida, N., Smith, L., Hanson, M. L., Steinhagen, F., Leighty, R. M., Roers, A., Karp, C. L., Müller, W., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65180 · Cited by 173 · see citing works
Zhang, L., Kosek, J., Wang, M., Heise, C. C., Schafer, P. H., & Chopra, R. (2012) · British Journal of Haematology · doi:10.1111/bjh.12172 · Cited by 167 · see citing works
Tarhini, A. A., Cherian, J., Moschos, S. J., Tawbi, H. A., Shuai, Y., Gooding, W. E., Sander, C., & Kirkwood, J. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.5394 · Cited by 148 · see citing works
Re-emergence of interferon-α in the treatment of chronic myeloid leukemia
Talpaz, M., Hehlmann, R., Quintás‐Cardama, A., Mercer, J., & Cortes, J. E. (2012) · Leukemia · doi:10.1038/leu.2012.313 · Cited by 139 · see citing works
The antitumor effects of IFN-α are abrogated in a STAT1-deficient mouse
Lesinski, G. B., Anghelina, M. I., Zimmerer, J. M., Bakalakos, T., Badgwell, B. D., Parihar, R., Hu, Y., Becknell, B., Abood, G. J., Chaudhury, A. R., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16603 · Cited by 135 · see citing works
Meixlsperger, S., Leung, C. S. K., Rämer, P. C., Pack, M., Vanoaica, L. D., Breton, G., Pascolo, S., Salazar, A. Μ., Dzionek, A., Schmitz, J., et al. (2013) · Blood · doi:10.1182/blood-2012-12-473413 · Cited by 128 · see citing works
Huang, L., Li, L., Lemos, H. D. P., Chandler, P., Pacholczyk, G. A., Baban, B., Barber, G. N., Hayakawa, Y., McGaha, T. L., Ravishankar, B., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301419 · Cited by 127 · see citing works
Aranda, F., Vacchelli, E., Eggermont, A. M. M., Galon, J., Fridman, W. H., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/onci.27297 · Cited by 113 · see citing works
Self-citationGenetic Engineering of Hematopoiesis for Targeted IFN-α Delivery Inhibits Breast Cancer Progression
Escobar, G., Moi, D., Ranghetti, A., Baydin, P. O., Squadrito, M. L., Kajaste‐Rudnitski, A., Bondanza, A., Gentner, B., Palma, M. D., Mazzieri, R., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3006353 · Cited by 113 · see citing works
Papewalis, C., Jacobs, B., Wuttke, M., Ullrich, E., Baehring, T., Fenk, R. R., Willenberg, H. S., Schinner, S., Cohnen, M., Seißler, J., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.3.1462 · Cited by 107 · see citing works
Interferon-α Suppresses cAMP to Disarm Human Regulatory T Cells
Bacher, N., Raker, V., Hofmann, C., Graulich, E., Schwenk, M., Baumgrass, R., Bopp, T., Zechner, U., Merten, L., Becker, C., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3788 · Cited by 103 · see citing works
Pardanani, A. (2013) · Blood · doi:10.1182/blood-2013-01-453183 · Cited by 101 · see citing works
Tschurtschenthaler, M., Wang, J., Fricke, C., Fritz, T. M. J., Niederreiter, L., Adolph, T. E., Sarcevic, E., Künzel, S., Offner, F. A., Kalinke, U., et al. (2014) · Gut · doi:10.1136/gutjnl-2013-305863 · Cited by 96 · see citing works
Passamonti, F. (2012) · Blood · doi:10.1182/blood-2012-02-366054 · Cited by 93 · see citing works
Therapeutic Activity of High-Dose Intratumoral IFN-β Requires Direct Effect on the Tumor Vasculature
Spaapen, R. M., Leung, M. Y. K., Fuertes, M. B., Kline, J. P., Zhang, L., Zheng, Y., Fu, Y., Luo, X., Cohen, K. S., & Gajewski, T. F. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401109 · Cited by 86 · see citing works
High efficiency cell-specific targeting of cytokine activity
Garcin, G., Paul, F., Staufenbiel, M., Bordat, Y., der Heyden, J. V., Wilmes, S., Cartron, G., Apparailly, F., Koker, S. D., Piehler, J., et al. (2014) · Nature Communications · doi:10.1038/ncomms4016 · Cited by 86 · see citing works
Moschella, F., Torelli, G. F., Valentini, M., Urbani, F., Buccione, C., Petrucci, M. T., Natalino, F., Belardelli, F., Foà, R., & Proietti, E. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3666 · Cited by 83 · see citing works
Aranda, F., Vacchelli, E., Obrist, F., Eggermont, A. M. M., Galon, J., Sautès‐Fridman, C., Cremer, I., ter Meulen, J. H., Zitvogel, L., Kroemer, G., et al. (2014) · OncoImmunology · doi:10.4161/onci.29179 · Cited by 81 · see citing works
Self-citationVacchelli, E., Aranda, F., Eggermont, A. M. M., Galon, J., Sautès‐Fridman, C., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/onci.27048 · Cited by 81 · see citing works
Self-citationKong, L.-Y., Wu, A., Doucette, T. A., Wei, J., Priebe, W., Fuller, G. N., Qiao, W., Sawaya, R. A., Rao, G., & Heimberger, A. B. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1693 · Cited by 80 · see citing works
Gungor, B., Yağcı, F. C., Tincer, G., Bayyurt, B., Alpdundar, E., Yildiz, S., Özcan, M., Gürsel, İ., & Gürsel, M. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007909 · Cited by 79 · see citing works
der Jeught, K. V., Joe, P. T., Bialkowski, L., Heirman, C., Daszkiewicz, L., Liechtenstein, T., Escors, D., Thielemans, K., & Breckpot, K. (2014) · Oncotarget · doi:10.18632/oncotarget.2463 · Cited by 79 · see citing works
Type I-IFNs control GVHD and GVL responses after transplantation
Robb, R. J., Kreijveld, E., Kuns, R. D., Wilson, Y. A., Olver, S. D., Don, A. L. J., Raffelt, N. C., de Weerd, N. A., Lineburg, K. E., Varelias, A., et al. (2011) · Blood · doi:10.1182/blood-2010-12-325746 · Cited by 72 · see citing works
Major depression during interferon-α treatment: vulnerability and prevention
Lotrich, F. E. (2009) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2009.11.4/felotrich · Cited by 71 · see citing works
Vacchelli, E., Aranda, F., Obrist, F., Eggermont, A. M. M., Galon, J., Cremer, I., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/onci.29030 · Cited by 64 · see citing works
Self-citationTrial Watch: Lenalidomide-based immunochemotherapy
Semeraro, M., Vacchelli, E., Eggermont, A. M. M., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.26494 · Cited by 60 · see citing works
Self-citationChen, H., Tanaka, N., Mitani, Y., Oda, E., Nozawa, H., Chen, J., Yanai, H., Negishi, H., Choi, M. K., Iwasaki, T., et al. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.01051.x · Cited by 59 · see citing works
Riley, C. H., Hansen, M., Brimnes, M. K., Hasselbalch, H. C., Bjerrum, O. W., Straten, P. T., Svane, I. M., & Jensen, M. K. (2014) · European Journal Of Haematology · doi:10.1111/ejh.12420 · Cited by 59 · see citing works
Interferon-α-secreting mesenchymal stem cells exert potent antitumor effect in vivo
Xu, C., Lin, L., Cao, G., Chen, Q., Shou, P., Huang, Y., Han, Y., Wang, Y., & Shi, Y. (2013) · Oncogene · doi:10.1038/onc.2013.458 · Cited by 57 · see citing works
Targeting IFN-α to B Cell Lymphoma by a Tumor-Specific Antibody Elicits Potent Antitumor Activities
Huang, T.-H., Chintalacharuvu, K. R., & Morrison, S. L. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.10.6881 · Cited by 51 · see citing works
Innate immune sensing of cancer: clues from an identified role for type I IFNs
Gajewski, T. F., Fuertes, M. B., & Woo, S. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1305-6 · Cited by 50 · see citing works
Koba, C., Haruta, M., Matsunaga, Y., Matsumura, K., Haga, E., Sasaki, Y., Ikeda, T., Takamatsu, K., Nishimura, Y., & Senju, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067567 · Cited by 50 · see citing works
Maeda, S., Wada, H., Naito, Y., Nagano, H., Simmons, S., Kagawa, Y., Naito, A., Kikuta, J., Ishii, T., Tomimaru, Y., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.551879 · Cited by 49 · see citing works
Guillot, B., Portalès, P., Du-Thanh, A., Merlet, S., Dereure, O., Clot, J., & Corbeau, P. (2005) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2005.06512.x · Cited by 48 · see citing works
Chan, S. R., Rickert, C. G., Vermi, W., Sheehan, K. C. F., Arthur, C. D., Allen, J. A., White, J. M., Archambault, J. M., Lonardi, S., McDevitt, T. M., et al. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.116 · Cited by 48 · see citing works
Hertler, C., Roth, P., Silginer, M., Florea, A., Lamszus, K., Frei, K., Deenen, R., Reifenberger, G., & Weller, M. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0772 · Cited by 48 · see citing works
Type I IFN gene delivery suppresses regulatory T cells within tumors
Hashimoto, H., Ueda, R., Narumi, K., Heike, Y., Yoshida, T., & Aoki, K. (2014) · Cancer Gene Therapy · doi:10.1038/cgt.2014.60 · Cited by 46 · see citing works
Melero, I., Quetglas, J. I., Reboredo, M., Dubrot, J., Rodríguez-Madoz, J. R., Mancheño, U., Casales, E., Riezu‐Boj, J. I., Ruiz-Guillen, M., Ochoa, M. C., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3356 · Cited by 41 · see citing works
Preclinical studies on targeted delivery of multiple IFNα2b to HLA-DR in diverse hematologic cancers
Rossi, E. A., Rossi, D. L., Cardillo, T. M., Stein, R., Goldenberg, D. M., & Chang, C. (2011) · Blood · doi:10.1182/blood-2011-03-343145 · Cited by 40 · see citing works
Ilander, M. M., Kreutzman, A. S., Rohoň, P., Melo, T. P. E., Faber, E., Porkka, K., Vakkila, J., & Mustjoki, S. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087794 · Cited by 40 · see citing works
Interferon α may be back on track to treat acute myeloid leukemia
Smits, E., Anguille, S., & Berneman, Z. N. (2013) · OncoImmunology · doi:10.4161/onci.23619 · Cited by 40 · see citing works
Badgwell, B. D., Lesinski, G. B., MAGRO, C. M. J., Abood, G. J., Skaf, A., & Carson, W. E. (2004) · Journal of Surgical Research · doi:10.1016/j.jss.2003.09.005 · Cited by 35 · see citing works
Interferons in the Treatment of Solid Tumors
Moschos, S. J., Varanasi, S. M., & Kirkwood, J. M. (2005) · Springer eBooks · doi:10.1007/0-387-24361-5_9 · Cited by 33 · see citing works
Bhattacharya, S., Zheng, H., Tzimas, C., Carroll, M. P., Baker, D. P., & Fuchs, S. Y. (2011) · Blood · doi:10.1182/blood-2010-12-325373 · Cited by 30 · see citing works
Jiang, W., Zhang, C., Tian, Z., & Zhang, J. (2013) · Gene Therapy · doi:10.1038/gt.2013.31 · Cited by 30 · see citing works
Snijders, A. M., Langley, S. A., Mao, J., Bhatnagar, S., Bjornstad, K. A., Rosen, C. J., Lo, A. T., Huang, Y., Blakely, E. A., Karpen, G. H., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2148 · Cited by 23 · see citing works
The Janus face of cyclophosphamide
Ziccheddu, G., Proietti, E., & Moschella, F. (2013) · OncoImmunology · doi:10.4161/onci.25789 · Cited by 23 · see citing works
Schnurr, M. M., & Duewell, P. (2013) · OncoImmunology · doi:10.4161/onci.24170 · Cited by 21 · see citing works
Phosphoinositide 3-kinase regulates a subset of interferon-alpha-stimulated genes
Hjortsberg, L., Lindvall, C. J., Corcoran, M., Arulampalam, V., Chan, D. C. W., Thyrell, L., Nordenskjöld, M., Grandér, D., & Tamm, K. P. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2006.10.022 · Cited by 19 · see citing works
Eggermont, A. M. M., Suciu, S., Santinami, M., Kruit, W. H. J., Testori, A., Marsden, J. R., Punt, C. J. A., Gore, M. E., MacKie, R., Dummer, R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.8506b · Cited by 19 · see citing works
Treatment of indolent primary cutaneous B-cell lymphomas with subcutaneous interferon-alfa
Vandersee, S., Terhorst‐Molawi, D., Humme, D., & Beyer, M. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.11.019 · Cited by 18 · see citing works
Hardan, I., Stanevsky, A., Volchek, Y., Tohami, T., Amariglio, N., Trakhtenbrot, L., Koren‐Michowitz, M., Shimoni, A., & Nagler, A. (2011) · Cytokine · doi:10.1016/j.cyto.2011.11.018 · Cited by 17 · see citing works
IFN-β-specific signaling via a unique IFNAR1 interaction
Kaur, S., & Platanias, L. C. (2013) · Nature Immunology · doi:10.1038/ni.2686 · Cited by 17 · see citing works
Interferon-α Treatment for Growing Teratoma Syndrome of the Testis
Inoue, M., Hisasue, S., Nagae, M., China, T., Saito, K., Isotani, S., Yamaguchi, R., Ide, H., Muto, S., & Horie, S. (2013) · Case Reports in Nephrology and Dialysis · doi:10.1159/000350897 · Cited by 12 · see citing works
Kreutzer, K., Bonnekoh, B., Franke, I., Ulrich, J., & Gollnick, H. (2004) · PubMed · Cited by 11 · see citing works
Zeidner, J. F., Gladstone, D. E., ZAHURAK, M. L., Matsui, W. H., Gocke, C. D., Jones, R. J., & Smith, B. D. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.05.012 · Cited by 11 · see citing works
LI, Y.-F., Wang, Q., ZHANG, T.-T., Li, L., WANG, J.-P., Guo-fu, D., & He, D. (2013) · Oncology Letters · doi:10.3892/ol.2013.1653 · Cited by 10 · see citing works
Kreutzer, K., Bonnekoh, B., Franke, I., & Gollnick, H. P. M. (2004) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1046/j.1439-0353.2004.04793.x · Cited by 8 · see citing works
Radesi-Sarghi, S., Arbion, F., Dartigeas, C., Delain, M., Benboubker, L., Hérault, O., Colombat, P., & Gyan, E. (2013) · Annals of Hematology · doi:10.1007/s00277-013-1934-7 · Cited by 6 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0012-4 · Cited by 6,680 · see citing works
Self-citationApproaches to treat immune hot, altered and cold tumours with combination immunotherapies
Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,414 · see citing works
Immunogenic cell death in cancer and infectious disease
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.107 · Cited by 3,119 · see citing works
Self-citationInflammation and tumor progression: signaling pathways and targeted intervention
Zhao, H., Wu, L., Yan, G., Chen, Y., Zhou, M., Wu, Y., & Li, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00658-5 · Cited by 2,907 · see citing works
Zhang, Y., & Zhang, Z. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-0488-6 · Cited by 2,815 · see citing works
NF-κB, inflammation, immunity and cancer: coming of age
Taniguchi, K., & Karin, M. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.142 · Cited by 2,679 · see citing works
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature · doi:10.1038/nature18300 · Cited by 1,771 · see citing works
RIG-I-like receptors: their regulation and roles in RNA sensing
Rehwinkel, J., & Gack, M. U. (2020) · Nature reviews. Immunology · doi:10.1038/s41577-020-0288-3 · Cited by 1,703 · see citing works
Autophagy in major human diseases
Klionsky, D. J., Petroni, G., Amaravadi, R. K., Baehrecke, E. H., Ballabio, A., Boya, P., Bravo‐San Pedro, J. M., Cadwell, K., Cecconi, F., Choi, A. M. K., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2021108863 · Cited by 1,585 · see citing works
Self-citationImmunological effects of conventional chemotherapy and targeted anticancer agents
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.10.012 · Cited by 1,530 · see citing works
Self-citationImmunogenic cell stress and death
Kroemer, G., Galassi, C., Zitvogel, L., & Galluzzi, L. (2022) · Nature Immunology · doi:10.1038/s41590-022-01132-2 · Cited by 1,353 · see citing works
Self-citationConsensus guidelines for the definition, detection and interpretation of immunogenic cell death
Galluzzi, L., Vitale, I., Warren, S., Adjemian, S., Agostinis, P., Buqué, A., Chan, T. A.-T., Coukos, G., Demaria, S., Deutsch, É., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000337 · Cited by 1,151 · see citing works
Self-citationLv, M., Chen, M., Zhang, R., Zhang, W., Wang, C., Zhang, Y., Wei, X., Guan, Y., Liu, J., Feng, K., et al. (2020) · Cell Research · doi:10.1038/s41422-020-00395-4 · Cited by 1,040 · see citing works
Harnessing innate immunity in cancer therapy
Demaria, O., Cornen, S., Daëron, M., Morel, Y., Medzhitov, R., & Vivier, E. (2019) · Nature · doi:10.1038/s41586-019-1593-5 · Cited by 957 · see citing works
Combination cancer immunotherapies tailored to the tumour microenvironment
Smyth, M. J., Ngiow, S. F., Ribas, A., & Teng, M. W. L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.209 · Cited by 944 · see citing works
Self-citationA STING-activating nanovaccine for cancer immunotherapy
Luo, M., Wang, H., Wang, Z., Cai, H., Lu, Z., Li, Y., Du, M., Huang, G., Wang, C., Chen, X., et al. (2017) · Nature Nanotechnology · doi:10.1038/nnano.2017.52 · Cited by 904 · see citing works
Autophagy in inflammation, infection, and immunometabolism
Deretic, V. (2021) · Immunity · doi:10.1016/j.immuni.2021.01.018 · Cited by 862 · see citing works
Clinical significance of tumor-infiltrating lymphocytes in breast cancer
Stanton, S. E., & Disis, M. L. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0165-6 · Cited by 824 · see citing works
Impact of microbiota on central nervous system and neurological diseases: the gut-brain axis
Ma, Q., Xing, C., Long, W., Wang, H. Y., Liu, Q., & Wang, R. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1434-3 · Cited by 752 · see citing works
Control of Metastasis by NK Cells
López‐Soto, A., Gonzalez, S. R., Smyth, M. J., & Galluzzi, L. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.06.009 · Cited by 730 · see citing works
Self-citationNecroptosis: Mechanisms and Relevance to Disease
Galluzzi, L., Kepp, O., Chan, F. K.-M., & Kroemer, G. (2016) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-052016-100247 · Cited by 721 · see citing works
Self-citationRadiotherapy combined with immunotherapy: the dawn of cancer treatment
Zhang, Z., Liu, X., Chen, D., & Yu, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01102-y · Cited by 695 · see citing works
Yang, R., Sun, L., Li, C.-F., Wang, Y.-H., Yao, J., Li, H., Yan, M., Chang, W., Hsu, J.-M., Cha, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21099-2 · Cited by 637 · see citing works
Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes
Stanton, S. E., Adams, S., & Disis, M. L. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.1061 · Cited by 632 · see citing works
Tang, T., Huang, X., Zhang, G., Hong, Z., Bai, X., & Liang, T. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00449-4 · Cited by 613 · see citing works
Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment
Lam, K. C., Araya, R. E., Huang, A., Chen, Q., Di Modica, M., Rodrigues, R. R., Lopès, A., Johnson, S. B., Schwarz, B., Bohrnsen, E., et al. (2021) · Cell · doi:10.1016/j.cell.2021.09.019 · Cited by 604 · see citing works
Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends
Sun, Q., Hong, Z., Zhang, C., Wang, L., Han, Z., & Ma, D. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01522-4 · Cited by 598 · see citing works
Lactate Is a Natural Suppressor of RLR Signaling by Targeting MAVS
Zhang, W., Wang, G., Xu, Z., Tu, H.-Q., Hu, F., Dai, J., Chang, Y., Chen, Y., Lu, Y., Zeng, H., et al. (2019) · Cell · doi:10.1016/j.cell.2019.05.003 · Cited by 598 · see citing works
Type I interferon response drives neuroinflammation and synapse loss in Alzheimer disease
Roy, E. R., Wang, B., Wan, Y.-W., Chiu, G., Cole, A., Yin, Z., Propson, N. E., Xu, Y., Jankowsky, J. L., Liu, Z., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci133737 · Cited by 563 · see citing works
Linking cellular stress responses to systemic homeostasis
Galluzzi, L., Yamazaki, T., & Kroemer, G. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0068-0 · Cited by 529 · see citing works
Self-citationMyeloid immunosuppression and immune checkpoints in the tumor microenvironment
Nakamura, K., & Smyth, M. J. (2019) · Cellular and Molecular Immunology · doi:10.1038/s41423-019-0306-1 · Cited by 521 · see citing works
Self-citationTargeting cytokine and chemokine signaling pathways for cancer therapy
Yi, M., Li, T., Niu, M., Zhang, H., Wu, Y., Wu, K., & Dai, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01868-3 · Cited by 491 · see citing works
Type I Interferon in Chronic Virus Infection and Cancer
Snell, L. M., McGaha, T. L., & Brooks, D. G. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.05.005 · Cited by 490 · see citing works
Targeting the IDO1/TDO2–KYN–AhR Pathway for Cancer Immunotherapy – Challenges and Opportunities
Cheong, J. E., & Sun, L. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.11.007 · Cited by 489 · see citing works
TBK1 and IKKε Act Redundantly to Mediate STING-Induced NF-κB Responses in Myeloid Cells
Balka, K. R., Louis, C., Saunders, T. L., Smith, A. M., Calleja, D. J., D’Silva, D. B., Moghaddas, F., Tailler, M., Lawlor, K. E., Zhan, Y., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.03.056 · Cited by 488 · see citing works
The host STING pathway at the interface of cancer and immunity
Corrales, L., McWhirter, S. M., Dubensky, T. W., & Gajewski, T. F. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86892 · Cited by 487 · see citing works
Dendritic cells in cancer: the role revisited
Veglia, F., & Gabrilovich, D. I. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2017.01.002 · Cited by 448 · see citing works
Negishi, H., Taniguchi, T., & Yanai, H. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028423 · Cited by 447 · see citing works
Interferons α and β in cancer: therapeutic opportunities from new insights
Borden, E. C. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0011-2 · Cited by 423 · see citing works
Fucikova, J. P., Špíšek, R., Kroemer, G., & Galluzzi, L. (2020) · Cell Research · doi:10.1038/s41422-020-0383-9 · Cited by 408 · see citing works
Self-citationAndersson, A., Larsson, L., Stenbeck, L., Salmén, F., Ehinger, A., Wu, S. Z., Al-Eryani, G., Roden, D., Swarbrick, A., Borg, Å., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26271-2 · Cited by 404 · see citing works
STING Agonists as Cancer Therapeutics
Amouzegar, A., Chelvanambi, M., Filderman, J. N., Storkus, W. J., & Luke, J. J. (2021) · Cancers · doi:10.3390/cancers13112695 · Cited by 404 · see citing works
Zhou, Y., Fei, M., Zhang, G., Liang, W., Lin, W., Wu, Y., Piskol, R., Ridgway, J. B., McNamara, E., Huang, H., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.01.014 · Cited by 399 · see citing works
First oncolytic virus approved for melanoma immunotherapy
Pol, J. G., Kroemer, G., & Galluzzi, L. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1115641 · Cited by 395 · see citing works
Self-citationDuong, E., Fessenden, T. B., Lutz, E., Dinter, T., Yim, L., Blatt, S., Bhutkar, A., Wittrup, K. D., & Spranger, S. (2022) · Immunity · doi:10.1016/j.immuni.2021.10.020 · Cited by 372 · see citing works
Trisomy 21 consistently activates the interferon response
Sullivan, K. D., Lewis, H. C., Hill, A. A., Pandey, A., Jackson, L. P., Cabral, J. M., Smith, K. P., Liggett, L. A., Gomez, E. B., Galbraith, M. D., et al. (2016) · eLife · doi:10.7554/elife.16220 · Cited by 362 · see citing works
Caspases Connect Cell-Death Signaling to Organismal Homeostasis
Galluzzi, L., López-Soto, A., Kumar, S., & Kroemer, G. (2016) · Immunity · doi:10.1016/j.immuni.2016.01.020 · Cited by 350 · see citing works
Self-citationTumor-derived IFN triggers chronic pathway agonism and sensitivity to ADAR loss
Liu, H., Golji, J., Brodeur, L. K., Chung, F. S., Chen, J. T., deBeaumont, R. S., Bullock, C., Jones, M. D., Kerr, G., Li, L., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0302-5 · Cited by 346 · see citing works
Three decades of messenger RNA vaccine development
Verbeke, R., Lentacker, I., De Smedt, S. C., & Dewitte, H. (2019) · Nano Today · doi:10.1016/j.nantod.2019.100766 · Cited by 342 · see citing works
Emerging roles of p53 and other tumour-suppressor genes in immune regulation
Muñoz‐Fontela, C., Mandinova, A., Aaronson, S. A., & Lee, S. W. (2016) · Nature reviews. Immunology · doi:10.1038/nri.2016.99 · Cited by 342 · see citing works
Type 1 Interferons Induce Changes in Core Metabolism that Are Critical for Immune Function
Wu, D., Sanin, D. E., Everts, B., Chen, Q., Qiu, J., Buck, M. D., Patterson, A. E., Smith, A. M., Chang, C., Liu, Z., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.06.006 · Cited by 331 · see citing works
Prolonged activation of innate immune pathways by a polyvalent STING agonist
Li, S., Luo, M., Wang, Z., Feng, Q., Wilhelm, J., Wang, X., Li, W., Wang, J., Cholka, A., Fu, Y., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-020-00675-9 · Cited by 323 · see citing works
Manganese salts function as potent adjuvants
Zhang, R., Wang, C., Guan, Y., Wei, X., Sha, M., Yi, M., Jing, M., Lv, M., Guo, W., Xu, J., et al. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00669-w · Cited by 321 · see citing works
DNA Damage and Cancer Immunotherapy: A STING in the Tale
Reisländer, T., Groelly, F. J., & Tarsounas, M. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.07.026 · Cited by 318 · see citing works
PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity
Gato, M., Zuazo, M., Arasanz, H., Ibáñez-Vea, M., de Lorenzo, L., Fernández-Hinojal, G., Vera, R., Smerdou, C., Martišová, E., Arozarena, I., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.07.075 · Cited by 310 · see citing works
Type I interferon-mediated tumor immunity and its role in immunotherapy
Yu, R., Zhu, B., & Chen, D. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04219-z · Cited by 309 · see citing works
Oncolytic Viruses for Cancer Therapy: Barriers and Recent Advances
Zheng, M., Huang, J., Tong, A., & Yang, H. (2019) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2019.10.007 · Cited by 302 · see citing works
Targeting mitochondria for cardiovascular disorders: therapeutic potential and obstacles
Bonora, M., Wieckowski, M. R., Sinclair, D. A., Kroemer, G., Pinton, P., & Galluzzi, L. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0074-0 · Cited by 299 · see citing works
Self-citationThe intracellular signalosome of PD-L1 in cancer cells
Escors, D., Gato, M., Zuazo, M., Arasanz, H., García-Granda, M. J., Vera, R., & Kochan, G. T. (2018) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-018-0022-9 · Cited by 299 · see citing works
Bourgeois‐Daigneault, M., Roy, D. G., Aitken, A. S., El-Sayes, N., Martin, N. T., Varette, O., Falls, T. J., St-Germain, L. E., Pelin, A., Lichty, B. D., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aao1641 · Cited by 291 · see citing works
Trial watch: STING agonists in cancer therapy
Le Naour, J., Zitvogel, L., Galluzzi, L., Vacchelli, E., & Kroemer, G. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1777624 · Cited by 289 · see citing works
Self-citationHorvath, L., Thienpont, B., Zhao, L., Wolf, D. G. F., & Pircher, A. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01260-z · Cited by 286 · see citing works
Sato-Kaneko, F., Yao, S., Ahmadi, A., Zhang, S. S., Hosoya, T., Kaneda, M. M., Varner, J. A., Pu, M., Messer, K. S., Guiducci, C., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.93397 · Cited by 283 · see citing works
Direct Antiviral Mechanisms of Interferon-Gamma
Kang, S., Brown, H. M., & Hwang, S. (2018) · Immune Network · doi:10.4110/in.2018.18.e33 · Cited by 280 · see citing works
Ni, Q., Zhang, F., Liu, Y., Wang, Z., Yu, G., Liang, B., Niu, G., Su, T., Zhu, G., Lu, G., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaw6071 · Cited by 279 · see citing works
Immunomodulation of the Tumor Microenvironment: Turn Foe Into Friend
Locy, H., de Mey, S., de Mey, W., Ridder, M. D., Thielemans, K., & Maenhout, S. K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02909 · Cited by 277 · see citing works
Estrogen Receptor Signaling in the Immune System
Chakraborty, B., Byemerwa, J. K., Krebs, T., Lim, F., Chang, C., & McDonnell, D. P. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac017 · Cited by 275 · see citing works
Non-canonical NF-κB Antagonizes STING Sensor-Mediated DNA Sensing in Radiotherapy
Hou, Y., Liang, H. L., Rao, E., Zheng, W., Huang, X., Deng, L., Zhang, Y., Yu, X., Xu, M. M., Mauceri, H. J., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.07.008 · Cited by 270 · see citing works
NK cells mediate clearance of CD8 <sup>+</sup> T cell–resistant tumors in response to STING agonists
Nicolai, C. J., Wolf, N., Chang, I.-C., Kirn, G., Marcus, A., Ndubaku, C. O., McWhirter, S. M., & Raulet, D. H. (2020) · Science Immunology · doi:10.1126/sciimmunol.aaz2738 · Cited by 268 · see citing works
The good and the bad faces of STAT1 in solid tumours
Meissl, K., Macho‐Maschler, S., Müller, M. M., & Strobl, B. (2015) · Cytokine · doi:10.1016/j.cyto.2015.11.011 · Cited by 264 · see citing works
Activating a collaborative innate-adaptive immune response to control metastasis
Sun, L., Kees, T., Almeida, A. S., Liu, B., He, X., Ng, D. C., Han, X., Spector, D. L., McNeish, I. A., Gimotty, P. A., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.08.005 · Cited by 263 · see citing works
STING activation in cancer immunotherapy
Su, T., Zhang, Y. L., Valerie, K. C., Wang, X., Lin, S., & Zhu, G. (2019) · Theranostics · doi:10.7150/thno.37574 · Cited by 258 · see citing works
Vacchelli, E., Eggermont, A. M. M., Sautès‐Fridman, C., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.24612 · Cited by 255 · see citing works
Self-citationcGAS/STING axis mediates a topoisomerase II inhibitor–induced tumor immunogenicity
Wang, Z., Chen, J., Hu, J., Zhang, H., Xu, F., He, W., Wang, X., Li, M., Lu, W., Zeng, G., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127471 · Cited by 253 · see citing works
Ma, Z., Li, X., Mao, Y., Chen, W., Huang, Z., Li, G., Yin, J., Liang, X., & Liu, Z. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.11.005 · Cited by 252 · see citing works
Cytosolic DNA Sensing in Organismal Tumor Control
Vanpouille-Box, C., Demaria, S., Formenti, S. C., & Galluzzi, L. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.05.013 · Cited by 250 · see citing works
Self-citationKatlinski, K. V., Gui, J., Katlinskaya, Y. V., Ortiz, A., Chakraborty, R., Bhattacharya, S., Carbone, C. J., Beiting, D. P., Girondo, M. A., Peck, A. R., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.01.004 · Cited by 248 · see citing works
Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors
Peyraud, F., & Italiano, A. (2020) · Cancers · doi:10.3390/cancers12061502 · Cited by 240 · see citing works
Trial watch: TLR3 agonists in cancer therapy
Le Naour, J., Galluzzi, L., Zitvogel, L., Kroemer, G., & Vacchelli, E. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1771143 · Cited by 239 · see citing works
Self-citationCell membrane coated-nanoparticles for cancer immunotherapy
Zeng, Y., Li, S., Zhang, S., Wang, L., Yuan, H., & Hu, F. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.02.023 · Cited by 238 · see citing works
AIM2 in health and disease: Inflammasome and beyond
Kumari, P. H., Russo, A. J., Shivcharan, S., & Rathinam, V. A. K. (2020) · Immunological Reviews · doi:10.1111/imr.12903 · Cited by 237 · see citing works
Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies
Gujar, S. A., Pol, J. G., Kim, Y., Lee, P. W. K., & Kroemer, G. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.11.006 · Cited by 234 · see citing works
Self-citationThe Impact of Radiation-Induced DNA Damage on cGAS-STING-Mediated Immune Responses to Cancer
Storozynsky, Q. T., & Hitt, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228877 · Cited by 233 · see citing works
Trial Watch: Toll-like receptor agonists in cancer immunotherapy
Smith, M. M., García-Martínez, E., Pitter, M. R., Fucikova, J. P., Špíšek, R., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1526250 · Cited by 232 · see citing works
Self-citationWang, S., Campos, J. S., Gallotta, M., Gong, M., Crain, C., Naik, E., Coffman, R. L., & Guiducci, C. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1608555113 · Cited by 231 · see citing works
Vaccine adjuvants as potential cancer immunotherapeutics
Temizoz, B., Kuroda, E., & Ishii, K. J. (2016) · International Immunology · doi:10.1093/intimm/dxw015 · Cited by 228 · see citing works
Zhang, Q., Green, M. D., Lang, X., Lazarus, J., Parsels, J. D., Wei, S., Parsels, L. A., Shi, J., Ramnath, N., Wahl, D. R., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0761 · Cited by 228 · see citing works
NEMO–IKKβ Are Essential for IRF3 and NF-κB Activation in the cGAS–STING Pathway
Fang, R., Wang, C., Jiang, Q., Lv, M., Gao, P., Yu, X., Mu, P., Zhang, R., Bi, S., Feng, J., et al. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1700699 · Cited by 227 · see citing works
Brown, M. C., Holl, E. K., Boczkowski, D., Dobrikova, E. Y., Mosaheb, M., Chandramohan, V., Bigner, D. D., Gromeier, M., & Nair, S. K. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan4220 · Cited by 226 · see citing works
Targeting innate immune pathways for cancer immunotherapy
Cao, L. L., & Kagan, J. C. (2023) · Immunity · doi:10.1016/j.immuni.2023.07.018 · Cited by 224 · see citing works
Systemic vaccination induces CD8+ T cells and remodels the tumor microenvironment
Baharom, F., Ramirez-Valdez, R. A., Khalilnezhad, A., Khalilnezhad, S., Dillon, M., Hermans, D., Fussell, S. C., Tobin, K. K. S., Dutertre, C., Lynn, G. M., et al. (2022) · Cell · doi:10.1016/j.cell.2022.10.006 · Cited by 220 · see citing works
An origin of the immunogenicity of in vitro transcribed RNA
Mu, X., Greenwald, E., Ahmad, S., & Hur, S. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky177 · Cited by 218 · see citing works
Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression
Hossain, D. M. S., Javaid, S., Cai, M., Zhang, C., Sawant, A., Hinton, M., Sathe, M., Grein, J., Blumenschein, W., Pinheiro, E. M., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci94586 · Cited by 216 · see citing works
Li, Z., Chu, Z., Yang, J., Qian, H., Xu, J., Chen, B., Tian, T., Chen, H., Xu, Y., & Wang, F. (2022) · ACS Nano · doi:10.1021/acsnano.2c08013 · Cited by 216 · see citing works
pH-degradable imidazoquinoline-ligated nanogels for lymph node-focused immune activation
Nuhn, L., Vanparijs, N., Beuckelaer, A. D., Lybaert, L., Verstraete, G., Deswarte, K., Lienenklaus, S., Shukla, N. M., Salyer, A. C. D., Lambrecht, B. N., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1600816113 · Cited by 215 · see citing works
cGAS–STING and Cancer: Dichotomous Roles in Tumor Immunity and Development
Ng, K. W., Marshall, E. A., Bell, J. C., & Lam, W. L. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.07.013 · Cited by 215 · see citing works
Origin and Consequences of Necroinflammation
Sarhan, M., Land, W. G., Tonnus, W., Hugo, C., & Linkermann, A. (2018) · Physiological Reviews · doi:10.1152/physrev.00041.2016 · Cited by 210 · see citing works
STAT2 is an essential adaptor in USP18-mediated suppression of type I interferon signaling
Arimoto, K., Löchte, S., Stoner, S. A., Burkart, C., Zhang, Y., Miyauchi, S., Wilmes, S., Fan, J.-B., Heinisch, J. J., Li, Z., et al. (2017) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3378 · Cited by 205 · see citing works
Dendritic cell derived exosomes loaded neoantigens for personalized cancer immunotherapies
Li, J., Li, J., Peng, Y., Du, Y., Yang, Z., & Qi, X. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.11.053 · Cited by 204 · see citing works
Tumor Immunity and Immunotherapy for HPV-Related Cancers
Shamseddine, A. A., Burman, B., Lee, N. Y., Zamarin, D., & Riaz, N. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1760 · Cited by 203 · see citing works
- Authors
- Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M. J., & Kroemer, G.
- Affiliations
- Université Paris-Sud (FR)
- Inserm (FR)
- The University of Queensland (AU)
- Corresponding author
- Kroemer, Guido
- Venue
- Nature Reviews Immunology
- Published
- 2015-06-01
- Volume
- 15
- Issue
- 7
- Pages
- 405-414
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- OpenAlex
- W1611944043
- Cited by
- 1,305
- References
- 128
- Citations by year
- 2026: 85 · 2025: 123 · 2024: 162 · 2023: 161 · 2022: 155 · 2021: 121 · 2020: 126 · 2019: 87 · 2018: 104 · 2017: 94 · 2016: 69 · 2015: 17 · 2013: 1
- FWCI
- 8.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Association pour la Recherche sur le Cancer
- Ligue Contre le Cancer
- Institut National Du Cancer
- Institute of Cancer Research
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- type I interferon, antitumor immunity, tumor surveillance, IFN-stimulated genes, oncolytic viruses, immunoadjuvant, chemotherapeutics, targeted anticancer agents, recombinant interferon, cancer immunotherapy
- MeSH terms
- Animals, Humans, Immunotherapy, Interferon Type I, Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
